Inc280研究
Web本试验主要研究终点是确定 inc280 的安全性、耐受性以及最大耐受剂量(mtd)或 ii 期试验推荐剂量(rp2d)。 次要研究终点包括初步的抗肿瘤活性和药代动力学(PK)。 Web薬剤:INC280 (capmatinib) フェーズ:第II相; 進捗状況:募集終了; 試験種別:企業治験(グローバル) 1又は2ラインの全身治療歴があるEGFR野生型の進行性/転移性非小細胞肺がん(NSCLC)成人患者を対象としたc-MET阻害剤INC280経口投与による多施設共同4コホート …
Inc280研究
Did you know?
http://www.scrum-japan.ncc.go.jp/lc_scrum/trial/egfrnsclcc-metinc280ii/index.html WebMar 12, 2015 · INC280 is a highly potent and selective c-MET inhibitor which also penetrates the blood-brain barrier. In this open-label, multicenter Phase 1b study, investigators determined the optimal dose of the INC280/bevacizumab combination to administer to patients. Enrollment has now expanded in order to treat 3 cohorts of GBM patients: those …
Web卡马替尼 (Capmatinib) (INC280)是一种研究性、口服、强效、选择性MET抑制剂,对MET的抑制能力远强于其他MET靶向药,如克唑替尼、沃利替尼 (Savolitinib)、Tepotinib。. 之 … WebMar 11, 2024 · INC280 treatment inhibits growth of a c-MET-amplified MKN45 (RUNX3-positive) and SNU620 (RUNX3-negative) diffuse type cells. Then, INC280 showed the …
WebJun 10, 2024 · 因此,2010年我们提出了第一个研究思路,考虑可以把c-met抑制剂inc280和吉非替尼两药联合起来以克服耐药。 在此思路下,我们开始了一系列临床I期、II期研究,就是非常有名的INC280联合吉非替治疗c-MET扩增肺癌患者的有效性及安全性研究。 WebDec 3, 2024 · 近年来,MET抑制剂的研究层出不穷,其中沃利替尼、Tepotinib和Capmatinib(卡马替尼,又名INC280)是目前研究数据相对较多的3个药物。 卡马替尼作为一种口服的高选择性小分子MET抑制剂,于2024年5月6日被美国FDA批准上市。
WebFeb 9, 2024 · 长春inc280片ii期临床试验-在egfr突变和cmet扩增的晚期非小细胞肺癌中进行的inc280研究 长春无开展的INC280片II期临床试验信息,需要患者受试者,主要适应症为非小细胞肺癌
WebApr 10, 2015 · Study Description. A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung … rdw sd 49.7 flWebOct 19, 2024 · Basel, October 19, 2024 - Novartis today announced Phase II preliminary results of the GEOMETRY mono-1 clinical trial of investigational MET inhibitor capmatinib … how to spell tilapia the fishWebJun 10, 2016 · The purpose of this study of INC280 and PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent or in combination with INC280 administered orally in adult patients with advanced hepatocellular carcinoma (HCC). how to spell tiltedhttp://www.kangantu.org/tumour/84502.html how to spell tilapiaWebMay 26, 2024 · 9004 Background: Capmatinib is a highly potent and selective MET inhibitor. Previous data of GEOMETRY mono-1 study showed a clinically meaningful overall response rate (ORR) and manageable toxicity profile in patients (pts) with METΔex14–mutated NSCLC who received 1–2 prior lines of treatment (tx) (Cohort 4) and in particular a high ORR in tx … how to spell tiltWebTI’s INA280 is a 2.7-V to 120-V, 1.1-MHz, high-precision current sense amplifier in small (SC-70) package. Find parameters, ordering and quality information rdw rbc rangeWebApr 29, 2024 · 该研究纳入了MET 14号外显子跳跃突变或MET扩增的晚期NSCLC患者,包括脑转移患者。 ... Capmatinib(INC280)是强力MET抑制剂,对MET的抑制能力远强于其他MET靶向药,如克唑替尼、沃利替尼(Savolitinib)、Tepotinib 。Capmatinib(INC280)的剂量为400mg,每天两次,口服。 rdw rotary website